1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/news/Dasatinib-studied-in-patients-with-leukemia-and-resistance-or-intolerance-to-imatinib-1983.html

Dasatinib studied in patients with leukemia and resistance or intolerance to imatinib

07-28-2006

Bristol-Myers Squibb presented results from four single-arm, open-label Phase II studies of dasatinib, an oral investigational compound.

The studies evaluated the efficacy and safety of dasatinib in patients in all chronic myeloid leukemia (CML) phases (chronic, accelerated and blast), and patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) no longer responding to or unable to tolerate current therapies, including imatinib.

Collectively, 789 patients were enrolled in the four studies. Patients were treated with dasatinib 70 mg twice daily; efficacy was assessed on the basis of their haematologic and cytogenetic responses and safety was assessed continuously. These studies suggest that dasatinib may be able to induce hematologic and cytogenetic responses in many patients with CML and Ph+ ALL with resistance or intolerance to imatinib.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2006, Biotech Business Week via NewsRx.com.